- 1.Lenvatinib for effectively treating antiangiogenic drug-resistant nasopharyngeal carcinoma
- 2.MORTALIN-Ca2+ axis drives innate rituximab resistance in diffuse large B-cell lymphoma
- 3.Mitochondria-specific peptide amphiphiles induce mitochondrial dysfunction and peripheral T-cell lymphomas (PTCL) damage
“和元李记”由和元生物 (股票代码:688238) 和李记生物合资成立的,主营“李记生物”“Life-ilab”试剂品牌
返回


